| Literature DB >> 28811343 |
Amit Ranjan1, Sabiha Shaik1, Nishant Nandanwar1, Arif Hussain1, Sumeet K Tiwari1, Torsten Semmler2,3, Savita Jadhav4, Lothar H Wieler2,3, Munirul Alam5, Rita R Colwell6,7,8, Niyaz Ahmed9,5.
Abstract
Escherichia coli, an intestinal Gram-negative bacterium, has been shown to be associated with a variety of diseases in addition to intestinal infections, such as urinary tract infections (UTIs), meningitis in neonates, septicemia, skin and soft tissue infections (SSTIs), and colisepticemia. Thus, for nonintestinal infections, it is categorized as extraintestinal pathogenic E. coli (ExPEC). It is also an opportunistic pathogen, causing cross infections, notably as an agent of zoonotic diseases. However, comparative genomic data providing functional and genetic coordinates for ExPEC strains associated with these different types of infections have not proven conclusive. In the study reported here, ExPEC E. coli isolated from SSTIs was characterized, including virulence and drug resistance profiles, and compared with isolates from patients suffering either pyelonephritis or septicemia. Results revealed that the majority of the isolates belonged to two pathogenic phylogroups, B2 and D. Approximately 67% of the isolates were multidrug resistant (MDR), with 85% producing extended-spectrum beta-lactamase (ESBL) and 6% producing metallo-beta-lactamase (MBL). The blaCTX-M-15 genotype was observed in at least 70% of the E. coli isolates in each category, conferring resistance to an extended range of beta-lactam antibiotics. Whole-genome sequencing and comparative genomics of the ExPEC isolates revealed that two of the four isolates from SSTIs, NA633 and NA643, belong to pandemic sequence type ST131, whereas functional characteristics of three of the ExPEC pathotypes revealed that they had equal capabilities to form biofilm and were resistant to human serum. Overall, the isolates from a variety of ExPEC infections demonstrated similar resistomes and virulomes and did not display any disease-specific functional or genetic coordinates.IMPORTANCE Infections caused by extraintestinal pathogenic E. coli (ExPEC) are of global concern as they result in significant costs to health care facilities management. The recent emergence of a multidrug-resistant pandemic clone, Escherichia coli ST131, is of primary concern as a global threat. In developing countries, such as India, skin and soft tissue infections (SSTIs) associated with E. coli are marginally addressed. In this study, we employed both genomic analysis and phenotypic assays to determine relationships, if any, among the ExPEC pathotypes. Similarity between antibiotic resistance and virulence profiles was observed, ST131 isolates from SSTIs were reported, and genomic similarities among strains isolated from different disease conditions were detected. This study provides functional molecular infection epidemiology insight into SSTI-associated E. coli compared with ExPEC pathotypes.Entities:
Keywords: Escherichia coli; genomics; sepsis
Mesh:
Substances:
Year: 2017 PMID: 28811343 PMCID: PMC5559633 DOI: 10.1128/mBio.01070-17
Source DB: PubMed Journal: mBio Impact factor: 7.867
Phylogenetic grouping, virulence, and antimicrobial resistance genotype of extraintestinal pathogenic E. coli included in this study
| Characteristic | Gene or | No. (%) of strains associated with infection: | ||
|---|---|---|---|---|
| Pyelonephritis | Septicemia | Skin and soft tissue | ||
| Phylogenetic grouping, (no. [%] of strains) | ||||
| A (18 [23]) | 2 (7) | 8 (30) | 8 (38) | |
| B1 (9 [12]) | 3 (10) | 4 (15) | 2 (10) | |
| B2 (28 [36]) | 15 (50) | 7 (26) | 6 (29) | |
| D (23 [29]) | 10 (33) | 8 (30) | 5 (24) | |
| Virulence factors | ||||
| Toxins | 16 (53) | 9 (33) | 6 (29) | |
| 10 (33) | 6 (22) | 6 (29) | ||
| 6 (20) | 6 (22) | 15 (71)* | ||
| Adhesins | 27 (90) | 24 (89) | 13 (62)* | |
| 28 (93) | 25 (93) | 5 (24)* | ||
| 8 (27) | 1 (4) | 1 (05) | ||
| 2 (7) | 2 (7) | 1 (05) | ||
| Protectins | 5 (17) | 4 (15) | 6 (29) | |
| 3 (10) | 3 (11) | 1 (5) | ||
| Iron acquisition | 27 (90) | 21 (78) | 16 (76) | |
| 19 (63) | 16 (59) | 15 (71) | ||
| Antibiotic resistance profiling: antibiotic class | ||||
| ESBL | 21 (70) | 24 (89) | 17 (81) | |
| 15 (50) | 14 (52) | 4 (19)* | ||
| 11 (37) | 12 (44) | 4 (19) | ||
| Metallo-beta-lactamase | 0 (0) | 1 (4) | 5 (24)* | |
| Tetracyclines | 20 (67) | 17 (63) | 8 (38) | |
| Aminoglycosides | 14 (47) | 10 (37) | 9 (43) | |
| Fluoroquinolone | 9 (30) | 13 (48) | 15 (71) | |
| Sulfonamides | 25 (83) | 23 (82) | 15 (71) | |
| 12 (40) | 7 (26) | 6 (29) | ||
| Trimethoprim | 8 (27) | 9 (33) | 2 (10) | |
| Integrin | 18 (60) | 15 (56) | 13 (62) | |
Total number of strains was 78.
Asterisks denote a P value of <0.05 compared to the septicemia group of strains.
Pathotypes and phenotypic drug resistance and multidrug resistance phenotypes
| Antimicrobial class | Specific drug | % overall prevalence of | Estimated fraction in infection type: | ||
|---|---|---|---|---|---|
| Pyelonephritis | Septicemia | Skin and soft tissue | |||
| Quinolone/fluoroquinolone | Ciprofloxacin | 86 | 0.37 | 0.34 | 0.28 |
| Sulfonamide/trimethoprim | Co-trimoxazole | 72 | 0.43 | 0.36 | 0.21 |
| Aminoglycosides | Gentamicin | 31 | 0.33 | 0.41 | 0.25 |
| Phenicols/phosphonic acid derivatives | Chloramphenicol | 23 | 0.39 | 0.50 | 0.11 |
| Fosfomycin | 5 | 0.00 | 0.25 | 0.75 | |
| Tetracyclines | Tetracycline | 77 | 0.43 | 0.35 | 0.22 |
| ESBL phenotype | Cefotaxime | 85 | 0.36 | 0.36 | 0.27 |
| MBL phenotype | Meropenem | 06 | 0.00 | 0.16 | 0.83 |
| Multidrug resistance | 67 | 0.40 | 0.32 | 0.26 | |
FIG 1 Heat map of virulome (a) and resistome (b) data generated from whole-genome comparative genomics for 12 strains that included four strains from each of the infection categories septicemia, pyelonephritis, and SSTI. Black boxes represent presence, and gray boxes represent absence.
Genome statistics for eight strains sequenced in this study
| Strain | Accession no. | No. of raw | Genome | No. of contigs | Sequence | Genome | No. of | Coding % | No. of | G+C | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NA643 | MJDL00000000 | 2,136,944 | 108.5 | 112 | ST131 | 5,322,063 | 5,257 | 87.4 | 17 | 50.72 | 216,749 |
| NA635 | MJDK00000000 | 1,822,696 | 91.8 | 122 | ST617 | 4,948,859 | 4,769 | 87.2 | 12 | 50.78 | 164,858 |
| NA633 | MJDJ00000000 | 1,878,242 | 94.6 | 81 | ST131 | 5,275,425 | 5,212 | 87.7 | 17 | 50.68 | 265,266 |
| NA447 | JWHS00000000 | 1,500,566 | 45 | 239 | ST617 | 5,091,202 | 4,990 | 85.7 | 15 | 50.68 | 52,237 |
| NA267 | MJDI00000000 | 2,092,350 | 105 | 164 | ST405 | 5,393,308 | 5,229 | 86.8 | 13 | 50.51 | 118,812 |
| NA259 | MJGD00000000 | 1,758,550 | 88.6 | 162 | ST405 | 5,400,321 | 5,260 | 86.9 | 13 | 50.51 | 118,812 |
| NA056 | MKHD00000000 | 1,513,364 | 78 | 98 | ST68 | 5,322,471 | 5,099 | 87.6 | 12 | 50.54 | 143,398 |
| NA057 | JSXL00000000 | 1,913,156 | 57 | 150 | ST38 | 5,286,256 | 5,173 | 86.5 | 8 | 50.5 | 120,832 |
CDS, coding sequences.
FIG 2 (a) BLAST Ring Image Generator (BRIG) images of 12 strains, including four from each infection category, where each concentric ring represents genomes sequentially in groups, e.g., septicemia, pyelonephritis, and SSTI, generated with the NA097 septicemia strain serving as a reference. (b) Serum resistance tested using 50% human serum. (c) Biofilm formation assay for 10 strains from each category, repeated twice in technical triplicate. ns, nonsignificant; SBF, specific biofilm formation; +ve, positive.
Prevalence of combinations of ESBL, CTX-M-15, fluoroquinolone resistance, co-trimoxazole resistance, and tetracycline resistance among isolates included in this study (n = 78)
| Subset | Subset definition | Total no. (%) of | No. of isolates (%) associated with infection type: | ||
|---|---|---|---|---|---|
| Pyelonephritis | Septicemia | Skin and soft tissue | |||
| 1 | ESBL+ CTX-M-15+ | 60 (77) | 21 (70) | 23 (85) | 16 (76) |
| 2 | ESBL+ CTX-M-15+ Tem+ | 30 (38) | 11 (37) | 12 (43) | 7 (33) |
| 3 | CTX-M-15+, fluoroquinolone resistant | 57 (73) | 20 (67) | 22 (81) | 15 (71) |
| 4 | CTX-M-15+, fluoroquinolone resistant, co-trimoxazole resistant | 44 (56) | 17 (56) | 17 (63) | 10 (48) |
| 5 | CTX-M-15+, fluoroquinolone susceptible, co-trimoxazole resistant | 2 (3) | 1 (3) | 1 (4) | 0 (0) |
| 6 | CTX-M-15+, fluoroquinolone resistant, co-trimoxazole susceptible | 13 (17) | 3 (10) | 5 (18) | 5 (24) |
| 7 | CTX-M-15+, fluoroquinolone susceptible, co-trimoxazole susceptible | 3 (4) | 0 (0) | 1 (4) | 2 (10) |
| 8 | CTX-M-15+, fluoroquinolone resistant, co-trimoxazole resistant, tetracycline resistant | 39 (50) | 17 (56) | 16 (57) | 6 (29) |
| 9 | CTX-M-15+, fluoroquinolone resistant, co-trimoxazole resistant, tetracycline susceptible | 4 (5) | 0 (0) | 0 (0) | 4 (19) |
| 10 | CTX-M-15−, fluoroquinolone susceptible | 6 (8) | 4 (13) | 2 (7) | 0 (0) |
Tem, temoniera-beta-lactamase.